Renalytix Plc specializes in developing artificial intelligence-driven in vitro diagnostic solutions for kidney diseases. Its flagship offering, KidneyIntelX, is a sophisticated diagnostic platform. This system leverages an AI-powered algorithm that integrates diverse data inputs, including validated blood-based biomarkers, an individual's inherited genetics, and personalized patient data extracted from electronic health records, to generate a unique risk score for each patient. These innovations serve several critical applications, such as diagnosing and forecasting the progression of kidney disease, guiding clinical patient management, aiding in patient selection for pharmaceutical trials, and discovering novel drug targets. The company has forged strategic alliances, including licensing agreements with prominent institutions. It collaborates with Mount Sinai Health System for the development and commercialization of AI-driven diagnostic tools for renal conditions. Another agreement is with Joslin Diabetes Center, Inc., focusing on developing and marketing products for kidney disease diagnosis and prediction using biomarkers. Additionally, a partnership with Kantaro Biosciences LLC is dedicated to creating and commercializing laboratory tests for detecting SARS-CoV-2 antibodies. Furthermore, Renalytix has formed a significant collaboration with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine. This alliance aims to implement an advanced clinical care model designed to bolster kidney health and mitigate the advancement of kidney disease and renal failure among at-risk populations. Incorporated in 2018, Renalytix Plc is headquartered in New York, New York. The company adopted its current name in June 2021, having previously operated as Renalytix AI plc.